Startups

Quince Therapeutics

Clinical-stage biotechnology company developing treatments for serious underserved diseases. Formerly Cortexyme, it is advancing LAM-001, an inhaled rapamycin candidate for pulmonary diseases, following its May 2026 acquisition of Orphai Therapeutics. Its earlier eDSP program used red-blood-cell drug encapsulation for ataxia-telangiectasia; the January 2026 Phase 3 study did not meet its primary endpoint.

Team

Aaron WaxmanScientific Advisory Board Member

Brendan HannahChief Operating Officer and Chief Business Officer

Brigette RobertsChief Corporate Affairs Officer and Board Member

Christopher SennerBoard Member

David LamondBoard Member

Dirk ThyeChief Executive Officer, Chief Medical Officer and Board Member

June BrayBoard Member

Paul YuScientific Advisory Board Member

Robert BaughmanScientific Advisory Board Member

Steve HaysScientific Advisory Board Member

Steven NathanScientific Advisory Board Member

Investments

$—Unknown date

Breakout Ventures